Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 2025 Earnings Presentation
10 slides from Phibro Animal Health's earnings presentation, Nov 7, 2024
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call November 7, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2025 First Quarter Ended September 30, 2024 November 7, 2024 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Continued Sales Strong Growth in Preliminary Estimates FY2025 Full Year Momentum Animal Health for the Zoetis Portfolio* Guidance Phibro Standalone Q1 Total Consolidated sales and Q1 Animal Health sales and For the eight months period in 2025 guidance adjusted EBITDA growth of 13% adjuste
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated First Quarter, Year-on-Year comparison $ in millions, except per share data Q1 Q1 YOY FY24 FY25 %∆ Consolidated Net Sales $ 231.3 $ 260.4 13% Net Income $ (8.0) $ 7.0 * Diluted EPS $ (0.20) $ 0.17 * Adjusted EBITDA $ 18.7 $ 30.7 64% Adjusted Net Income $ 5.5 $ 14
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health First Quarter, Year-on-Year comparison $ in millions Q1 Q1 YOY FY24 FY25 %∆ Animal Health Net Sales $ 160.5 $ 182.5 14% MFAs & other 94.1 107.8 15% Nutritional specialties 40.2 42.6 6% Vaccines 26.2 32.0 22% Adj. EBITDA $ 28.5 $ 40.4 42% Adj. EBITDA Margin 17.7%
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments First Quarter, Year-on-Year comparison $ in millions Q1 Q1 YOY FY24 FY25 %∆ Mineral Nutrition Net Sales $ 56.0 $ 59.1 5% Adj. EBITDA $ 2.9 $ 3.8 31% Adj. EBITDA Margin 5.1% 6.4% +130 bps Performance Products Net Sales $ 14.8 $ 18.8 27% Adj. EBITDA $ 1.4 $ 2.3 6
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics September 30, 2024 Free cash flow was $41 million for the TTM -- positive cash from operating activities of $84 million, less capital expenditures of $(43) million. Free Cash Flow (1) Cash and cash equivalents and short-term investments of $90 million 3.9x gross leverage r
Slide 8: 2024 Credit Facilities
2024 Credit Facilities Executed on July 3, 2024 The 2024 Credit Facilities: had an initial aggregate principal amount of $610 million, consisting of a $300 million Term A Loan and a $310 million Revolver included a $300 million Term A Loan, which replaced the Company’s existing 2021 Term A Loan
Slide 9: Financial Guidance – Phibro Standalone (excluding Zoetis MFA acquisition)
Financial Guidance – Phibro Standalone (excluding Zoetis MFA acquisition) Fiscal Year 2025 $ in millions, except earnings per share (EPS) data FY 2024 FY 2025 FY 2025 Previous Updated Actual Low High Low High Consolidated Net Sales $ 1,018 $ 1,040 $ 1,090 $ 1,050 $ 1,100 Net Income $ 2 $ 32 $ 38 $ 3
Slide 10: Q&A
PAHC Company Overview Q&A 10 November 7, 2024 Webcast and Conference Call